Review Tuesday, September 7


The growth of Nordic life sciences, investment opportunities, healthtech innovation and more. 

All time in CET (EET = +1hr / BST = -1hr / EST = -6hr)


09:00 LSX Welcome

Josh Dance, SVP, LSX
Josh Dance
, SVP, LSX

 


09:10 How Nasdaq Nordics Markets are Driving Growth Capital for Nordic Life Sciences

Adam Kostyal, SVP, Nasdaq (moderator)
Adam Kostyal
, SVP, Nasdaq

 


10:00 Nordic Life Sciences, Further Globally Recognised – What’s Next for the Thriving Ecosystem?

Whilst a challenging year for many reasons,2020 felt like a step change for the Nordics, putting an already attractive region even more firmly on the map. A number of companies passed significant private and public fundraising, clinical and company development milestones, and these positives stories continued through into 2021.

While the life sciences and healthcare industry was put ever-more under focus, in the Nordics particularly the increased capital flow and interest from international investors, pharma and other key stakeholders interested in playing their part to continue to build the maturing Nordic ecosystem was clear to see. What is next for the sector as a whole and how are these companies planning to grow, develop and internationalise further?

  • Stories of success in a time of isolation – how have companies passed key milestones while connections are harder?
  • Which models have been adopted for building companies – local and organic growth vs. more rapid global expansion?
  • What next for the Nordic regions next-wave life science leaders?

Martin Welschof, CEO, BioInvent 300x
Martin Welschof, CEO, BioInvent 


Anders Martin-Löf, CFO, Oncopeptides

Anders Martin-Löf, CFO, Oncopeptides 


Renee Aguiar-Lucander, CEO, Calliditas Therapeutics

Renee Aguiar-Lucander, CEO, Calliditas Therapeutics 


Josh Dance 200x (1)

Moderator: Josh Dance, SVP, LSX 

 


11:00 Success in Investment in the Nordics and Europe – Time to Recalibrate?

While challenges, opportunities and focus areas for investment are often discussed at length, what does analysis of key wider industry trends tell us about the true dynamics of European life sciences investment, and how it’s changing? Leading Nordic and European investors discuss what learnings can investors and companies alike take from key investment metrics.

  • Do ever-increasing larger financing rounds really mean venture multiples talked about are a realistic outcome in European life sciences investments?
  • How dependent is the European life sciences venture capital dependant on well-functioning public markets? How useful is it to benchmark with the US system?
  • With increased US capital into early-stage European life sciences, will these dynamics shift?
  • When do PIPEs and VCs making investments in public companies make sense, for the companies and investors? Is this an untapped opportunity for the large cohort of public Nordic life sciences companies?

Søren Lemonius, Managing General Partner, Sunstone Life Science Ventures
Søren Lemonius, Managing General Partner, Sunstone Life Science Ventures


Soren Moller

Søren Moller, Managing Partner, Novo Seeds 


Ingrid Teigland Akay, Managing Partner, Hadean Ventures

Ingrid Teigland Akay, Managing Partner, Hadean Ventures 


Tony Proctor, Partner, Potter Clarkson

Moderator:
Tony Proctor, Partner, Potter Clarkson

 


13:00 Masterclass: How to Optimize Biotech Drug Development Delivery Strategy

Strategic partnerships now play an increasing role in transforming the drug development process. A more structured, yet tailored approach combines acceleration with improved quality and compliance and allows for better insights and decision making. Effective partnerships are those that fit with both party’s needs, at the right times, and in the most suitable way, and this is key to the biotech’s success. This session presents a case study and lessons that can be learned from the effective collaboration along the drug development journey between a CRO and a biotech company.

Luke Gill, VP Clinical Development Services, TFS Health Science
Luke Gill, VP Clinical Development Services, TFS HealthScience


David Bejker, CEO Affibody

David Bejker, CEO, Affibody

 


14:00 Leading European Healthtech Innovation – Investment, Expansion and Internationalisation

While the wider European healthtech market is booming, the Nordics has become a frontrunner in digital innovation in healthcare. Nordic digital health and healthech innovation is gaining massive traction and attracting major investment. What has been key to this success and what is needed to secure the region as a globally competitive digital health innovation hub?

  • How has the Nordic region built such an innovative an internationally competitive digital ecosystem?
  • Investment trends in the healthtech – will the capital keep flowing, and what do investors need to see to fund the next generation of innovation?
  • What are the next steps for the regions leading healthtech businesses in further expansion and internationalisation?

Anna-Karin Edstedt Bonamy, CEO, Doctrin 300x
Anna-Karin Edstedt Bonamy, CEO, Doctrin 


André Sode, CEO, Liva Healthcare

André Sode, CEO, Liva Healthcare


John Drakenberg Renander, CEO, Alex Therapeutics

John Drakenberg Renander, CEO, Alex Therapeutics


Eric Teder, Operations Director and Country Manager Sweden, Doktor.se

Eric Teder, Country Manager Sweden, Doktor.se

Jeremy McCrohan, Head of Investor Relations, Norway Healthtech
Moderator: Jeremy McCrohan, Head of Investor Relations, Norway Healthtech

 


15:00 Global Registrations – Synergies Between US and Europe Medical Device Registration

  • Planning your development activities so that documentation and generated data can be used in submissions
  • Key considerations when planning FDA submission straight from CE mark
  • Which first? Pros and cons of targeting FDA approval or CE mark first
  • With FDA approval in place, what can be recycled for CE mark?
  • An integrated look at clinical strategy to fulfil RA needs in both EU and US

Jan Bart Hak, Head Medical Device Department, ProPharma Group
Jan Bart Hak, Head of Medical Device Department, ProPharma Group 

 


15:30 Opportunities In Iowa's Onehealth Sector - Location Advantages For Nordic And European Companies In The Midwest

Building a US presence at the right time is key for growing and internationalising European businesses. One Health is the integrative effort of multiple disciplines working locally, nationally, and globally to attain optimal health for people, animals, and the environment. Together, the three make up the One Health triad, and the health of each is inextricably connected to the others. Understanding and addressing the health issues created at this intersection is the foundation for the concept of One Health. The State of Iowa is well positioned, both, from a geographic as well as institutional and infrastructure position, to help businesses grow in this sector. This presentation will highlight:

  • Iowa’s assets in promoting the concept ‘One Health’
  • Location advantages for companies planning to expand in the Midwest
  • IEDA assistance and support programs

Mark Laurenzo, Business Development Manager, Iowa Economic Development Authority
Mark Laurenzo, Business Development Manager, Iowa Economic Development Authority

 


16:00 Preparing for and Executing Successful Cross-Border Transactions

Life sciences is a global industry and cross-border deals are often critical for growth and internationalisation plans. Scientific, market, structural and cultural challenges are all key considerations in successful licencing, partnering or M&A deal across borders. Executives explore the optimal means of preparation of materials, readiness with relevant data and planning, as well as the pitfalls in these critical endeavours.

  • Starting dialogues and creating partnerships - what needs to be in place, anticipated and planned early to be successful?
  • What are the most common challenges and pitfalls companies face in executing transactions and international partnerships?
  • Europe, the US and beyond – building a long-term global strategy

Søren Bregenholt, CEO, Macrophage 300x
Søren Bregenholt, CEO, Alligator Bioscience 


Magnus Corfitzen, CEO, Ascelia Pharma

Magnus Corfitzen, CEO, Ascelia Pharma 


Gunilla Oswald, CEO, BioArctic

Gunilla Oswald, CEO, BioArctic 


Nathalie Ter Wengel 300x

Nathalie ter Wengel, European Lead Worldwide Business Development, Pfizer 


Gregory Benning, MD & Group Head M&A, Back Bay Life Science Advisors 300x

Moderator:
Greg Benning, Managing Director, Back Bay Life Science Advisors

 

DOWNLOAD BROCHURE